
Joel W Hay

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4534610/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Effect of Behavioral Interventions on Inappropriate Antibiotic Prescribing Among Primary Care Practices. JAMA - Journal of the American Medical Association, 2016, 315, 562.	7.4	663
2	Effectiveness of a lifestyle intervention in promoting the well-being of independently living older people: results of the Well Elderly 2 Randomised Controlled Trial. Journal of Epidemiology and Community Health, 2012, 66, 782-790.	3.7	327
3	Examining the Value and Quality of Health Economic Analyses: Implications of Utilizing the QHES. Journal of Managed Care Pharmacy, 2003, 9, 53-61.	2.2	260
4	Development and Validation of a Grading System for the Quality of Cost-Effectiveness Studies. Medical Care, 2003, 41, 32-44.	2.4	253
5	Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 1992, 14, 309-317.	2.2	222
6	Costs of Necrotizing Enterocolitis and Cost-Effectiveness of Exclusively Human Milk-Based Products in Feeding Extremely Premature Infants. Breastfeeding Medicine, 2012, 7, 29-37.	1.7	176
7	Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report—Part II. Value in Health, 2010, 13, 8-13.	0.3	120
8	Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 1992, 14, 318-327.	2.2	107
9	Evaluation of Strategies for Use of Acellular Pertussis Vaccine in Adolescents and Adults: A Cost-Benefit Analysis. Clinical Infectious Diseases, 2004, 39, 20-28.	5.8	107
10	Cost-Effectiveness of Preventive Occupational Therapy for Independent-Living Older Adults. Journal of the American Geriatrics Society, 2002, 50, 1381-1388.	2.6	106
11	Cost-Effectiveness of Pravastatin in Secondary Prevention of Coronary Artery Disease**This study was supported by Bristol-Myers Squibb, Plainsboro, New Jersey American Journal of Cardiology, 1996, 78, 409-414.	1.6	99
12	Medical costs of coronary artery disease in the United States. American Journal of Cardiology, 1990, 65, 432-440.	1.6	93
13	Antidepressant Use in Geriatric Populations: The Burden of Side Effects and Interactions and Their Impact on Adherence and Costs. American Journal of Geriatric Psychiatry, 2011, 19, 211-221.	1.2	88
14	Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report—Part I. Value in Health, 2010, 13, 3-7.	0.3	81
15	Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective: The ISPOR Drug Cost Task Force Report—Part VI. Value in Health, 2010, 13, 28-33.	0.3	80
16	Pharmacoeconomics of Lipid-Lowering Agents for Primary and Secondary Prevention of Coronary Artery Disease. Pharmacoeconomics, 1999, 15, 47-74.	3.3	77
17	Using Conjoint Analysis to Assess Depression Treatment Preferences Among Low-Income Latinos. Psychiatric Services, 2004, 55, 934-936.	2.0	71
18	Long term healthcare costs of infants who survived neonatal necrotizing enterocolitis: a retrospective longitudinal study among infants enrolled in Texas Medicaid. BMC Pediatrics, 2013, 13, 127.	1.7	71

#	Article	IF	CITATIONS
19	An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. American Journal of Cardiology, 1991, 67, 789-796.	1.6	69
20	The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: A propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database. American Heart Journal, 2007, 154, 267-277.	2.7	63
21	Cost-Effectiveness Analysis of Collaborative Care Management of Major Depression among Low-Income, Predominantly Hispanics with Diabetes. Value in Health, 2012, 15, 249-254.	0.3	58
22	Physician-induced demand. Journal of Health Economics, 1982, 1, 231-244.	2.7	57
23	A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men. Clinical Infectious Diseases, 2016, 63, 1495-1504.	5.8	53
24	Effectiveness of Collaborative Care in Addressing Depression Treatment Preferences Among Low-Income Latinos. Psychiatric Services, 2010, 61, 1112-1118.	2.0	52
25	A US Population Health Survey on the Impact of COVID-19 Using the EQ-5D-5L. Journal of General Internal Medicine, 2021, 36, 1292-1301.	2.6	51
26	A Review of the Economic Burden of Glioblastoma and the Cost Effectiveness of Pharmacologic Treatments. Pharmacoeconomics, 2014, 32, 1201-1212.	3.3	49
27	Costâ€effectiveness analysis of lapatinib in HERâ€⊋–positive advanced breast cancer. Cancer, 2009, 115, 489-498.	4.1	48
28	Cost Effectiveness of Tumour Necrosis Factor-?? Inhibitors as First-Line Agents in Rheumatoid Arthritis. Pharmacoeconomics, 2006, 24, 1221-1232.	3.3	47
29	Let Them Eat Cake: A Note on Comparing Alternative Models of the Demand for Medical Care. Journal of Business and Economic Statistics, 1984, 2, 279.	2.9	46
30	Cost-benefit analysis of Haemophilus influenzae type b prevention. Pediatric Infectious Disease Journal, 1990, 9, 246-251.	2.0	38
31	Cost-Effectiveness of Primary Implanted Cardioverter Defibrillator for Sudden Death Prevention in Congestive Heart Failure. Cardiovascular Drugs and Therapy, 2004, 18, 161-170.	2.6	38
32	Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States. Clinical Colorectal Cancer, 2018, 17, e751-e761.	2.3	37
33	Cost-Effectiveness Analysis of Pharmaceutical Care in a Medicare Drug Benefit Program. Value in Health, 2003, 6, 425-435.	0.3	35
34	Asthma costs and utilization in a managed care organization. Journal of Allergy and Clinical Immunology, 2008, 121, 885-892.e5.	2.9	35
35	Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer. Gynecologic Oncology, 2014, 132, 677-683.	1.4	32
36	Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States. International Journal of Cardiology, 2015, 181, 417-424	1.7	32

#	Article	IF	CITATIONS
37	The Kaiser Permanente/USC Patient Consultation Study: Change in use and cost of health care services. American Journal of Health-System Pharmacy, 1998, 55, 2485-2499.	1.0	31
38	First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective. Lung Cancer, 2018, 123, 166-171.	2.0	31
39	The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. Neuro-Oncology, 2013, 15, 1532-1542.	1.2	29
40	Panel 2: Methodological Issues in Conducting Pharmacoeconomic Evaluations—Modeling Studies. Value in Health, 1999, 2, 78-81.	0.3	28
41	Economic Considerations for Pertussis Booster Vaccination in Adolescents. Pediatric Infectious Disease Journal, 2005, 24, S127-S133.	2.0	28
42	Cost Effectiveness of Treating Low HDL-Cholesterol in the Primary Prevention of Coronary Heart Disease. Pharmacoeconomics, 2005, 23, 133-141.	3.3	28
43	Evaluation and review of pharmacoeconomic models. Expert Opinion on Pharmacotherapy, 2004, 5, 1867-1880.	1.8	27
44	Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States. Pharmacoeconomics, 2013, 31, 823-839.	3.3	27
45	Cost-Effectiveness Analysis of Abiraterone and Sipuleucel-T in Asymptomatic Metastatic Castration-Resistant Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1417-1425.	4.9	27
46	Depression treatment preferences of older white and Mexican origin men. General Hospital Psychiatry, 2013, 35, 59-65.	2.4	26
47	Comparative Effectiveness of a Technology-Facilitated Depression Care Management Model in Safety-Net Primary Care Patients With Type 2 Diabetes: 6-Month Outcomes of a Large Clinical Trial. Journal of Medical Internet Research, 2018, 20, e147.	4.3	26
48	Cost-Effectiveness of a Technology-Facilitated Depression Care Management Adoption Model in Safety-Net Primary Care Patients with Type 2 Diabetes. Value in Health, 2018, 21, 561-568.	0.3	25
49	Lifestyle intervention for adults with spinal cord injury: Results of the USC–RLANRC Pressure Ulcer Prevention Study. Journal of Spinal Cord Medicine, 2019, 42, 2-19.	1.4	25
50	The Impact of Public Health Care Financing Policies on Private-Sector Hospital Costs. Journal of Health Politics, Policy and Law, 1983, 7, 945-952.	1.9	24
51	Understanding patient preferences and willingness to pay for hemophilia therapies. Patient Preference and Adherence, 2015, 9, 1623.	1.8	24
52	Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States. Annals of Pharmacotherapy, 2019, 53, 134-143.	1.9	24
53	Effects of ambulatory-care pharmacist consultation on mortality and hospitalization. American Journal of Managed Care, 2003, 9, 45-56.	1.1	24
54	Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and Other US Government Payers Perspectives: The ISPOR Drug Cost Task Force Report—Part IV. Value in Health, 2010, 13, 18-24.	0.3	22

#	Article	IF	CITATIONS
55	Estimating the association between metabolic risk factors and marijuana use in U.S. adults using data from the continuous National Health and Nutrition Examination Survey. Annals of Epidemiology, 2015, 25, 486-491.	1.9	22
56	Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β1a in Relapsing-Remitting Multiple Sclerosis. CNS Drugs, 2015, 29, 71-81.	5.9	22
57	A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Opinion on Pharmacotherapy, 2007, 8, 2775-2787.	1.8	21
58	Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective: The ISPOR Drug Cost Task Force Report—Part III. Value in Health, 2010, 13, 14-17.	0.3	21
59	Ordinary Least Squares and Sample-Selection Models of Health-Care Demand: Monte Carlo Comparison. Journal of Business and Economic Statistics, 1987, 5, 499.	2.9	20
60	Behavioral Economics Interventions to Improve Outpatient Antibiotic Prescribing for Acute Respiratory Infections: a Cost-Effectiveness Analysis. Journal of General Internal Medicine, 2019, 34, 846-854.	2.6	20
61	Measuring the impact of patient counseling in the outpatient pharmacy setting: the research design of the Kaiser permanente/USC patient consultation study. Clinical Therapeutics, 1995, 17, 1188-1206.	2.5	19
62	Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensityâ€score and instrumental variable methods to adjust for treatmentâ€selection bias. Pharmacoepidemiology and Drug Safety, 2012, 21, 470-484.	1.9	19
63	Implementing trials of complex interventions in community settings: The USC–Rancho Los Amigos Pressure Ulcer Prevention Study (PUPS). Clinical Trials, 2014, 11, 218-229.	1.6	19
64	Cost Impact of Diagnostic Imaging for Lower Extremity Peripheral Vascular Occlusive Disease. Value in Health, 2009, 12, 262-266.	0.3	18
65	Cost-Effectiveness Analysis of the Bivalent and Quadrivalent Human Papillomavirus Vaccines from a Societal Perspective in Colombia. PLoS ONE, 2013, 8, e80639.	2.5	17
66	Economical comparison of APCC vs. rFVIIa for mildâ€toâ€noderate bleeding episodes in haemophilia patients with inhibitors. Haemophilia, 2011, 17, e969-74.	2.1	16
67	Implementation and Outcomes of Commercial Disease Management Programs in the United States: The Disease Management Outcomes Consolidation Survey. Disease Management: DM, 2005, 8, 253-264.	1.0	15
68	A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma. Journal of Asthma, 2019, 56, 872-881.	1.7	15
69	Early onset sepsis calculator-based management of newborns exposed to maternal intrapartum fever: a cost benefit analysis. Journal of Perinatology, 2019, 39, 571-580.	2.0	15
70	Econometric issues in modeling the costs of AIDS. Health Policy, 1989, 11, 125-145.	3.0	14
71	Economic Modeling and Sensitivity Analysis. Value in Health, 1998, 1, 187-193.	0.3	14
72	Where's the Value in Health Care?. Value in Health, 2006, 9, 141-143.	0.3	14

#	Article	IF	CITATIONS
73	Cost-effectiveness of rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function. International Journal of Cardiology, 2019, 282, 53-58.	1.7	14
74	Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection. Clinical Microbiology and Infection, 2021, 27, 1448-1454.	6.0	14
75	Cost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD. Expert Review of Pharmacoeconomics and Outcomes Research, 2004, 4, 625-634.	1.4	13
76	Cost-Effectiveness Analysis of Rizatriptan and Sumatriptan versus Cafergot?? in the Acute Treatment of Migraine. CNS Drugs, 2005, 19, 635-642.	5.9	13
77	Cost and resource utilization comparisons of second-generation antihistamines vs. montelukast for allergic rhinitis treatment. Allergy and Asthma Proceedings, 2009, 30, 634-642.	2.2	13
78	Cost-Benefit Analysis of In-Hospital Influenza Vaccination of Postpartum Women. Obstetrics and Gynecology, 2012, 119, 306-314.	2.4	13
79	Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 267-283.	1.4	13
80	Prescriber preferences for behavioural economics interventions to improve treatment of acute respiratory infections: a discrete choice experiment. BMJ Open, 2016, 6, e012739.	1.9	13
81	Health Care Costs and Outcomes: How Should We Evaluate Real World Data?. Value in Health, 1999, 2, 417-419.	0.3	11
82	Appropriate Econometric Methods for Pharmacoeconometric Studies of Retrospective Claims Data: An Introductory Guide. Journal of Managed Care Pharmacy, 2005, 11, 344-348.	2.2	11
83	Using Pharmacoeconomics to Value Pharmacotherapy. Clinical Pharmacology and Therapeutics, 2008, 84, 197-200.	4.7	11
84	Efficacy of Bypassing Agents in Patients With Hemophilia and Inhibitors: A Systematic Review and Meta-Analysis. Clinical Therapeutics, 2012, 34, 434-445.	2.5	11
85	Hospital cost drivers: an evaluation of 1998-2001 state-level data. American Journal of Managed Care, 2003, 9 Spec No 1, SP13-24.	1.1	11
86	Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: An Industry Perspective: The ISPOR Drug Cost Task Force Report—Part V. Value in Health, 2010, 13, 25-27.	0.3	10
87	Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa. Journal of Medical Economics, 2011, 14, 516-525.	2.1	9
88	Costâ€Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate‣evere Crohn's Disease in Biologicâ€NaÃ⁻ve Patients. Pharmacotherapy, 2019, 39, 118-128.	2.6	9
89	Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S. General Dentistry, 2010, 58, 484-92; quiz 493-4.	0.4	9
90	Cost and Utilization Impacts of Oral Antihistamines in the California Medi-Cal Program. Value in Health, 2005, 8, 506-516.	0.3	8

#	Article	IF	CITATIONS
91	A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 149-157.	0.9	8
92	Now Is the Time for Transparency in Value-Based Healthcare Decision Modeling. Value in Health, 2019, 22, 564-569.	0.3	8
93	Costs of second-generation antihistamines in the treatment of allergic rhinitis: US perspective. Current Medical Research and Opinion, 2009, 25, 1421-1431.	1.9	7
94	Cost–benefit analysis of hospital based postpartum vaccination with combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap). Vaccine, 2013, 31, 2558-2564.	3.8	7
95	Neonates with mild hypoxic–ischaemic encephalopathy receiving supportive care versus therapeutic hypothermia in California. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2021, , fetalneonatal-2021-322250.	2.8	7
96	Quality of Life in the Swedish General Population During COVID-19 - Based on pre- and post-pandemic outbreak measurement. Nordic Journal of Health Economics, 2021, 9, 56-73.	0.2	7
97	Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapy. Journal of Medical Economics, 2013, 16, 1082-1088.	2.1	6
98	Outcomes and Utilization of Adjuvant Chemotherapy for Stage II Colon Cancer in the Oxaliplatin Period. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 428-434.	1.3	6
99	Cost-Effectiveness Analysis of Four Common Diagnostic Methods for Clostridioides difficile Infection. Journal of General Internal Medicine, 2020, 35, 1102-1110.	2.6	6
100	Commentary on Knight <i>etÂal.</i> : A systematic review of the costâ€effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors. Haemophilia, 2010, 16, 366-368.	2.1	5
101	There is Insufficient Evidence to Support a Causal Relationship Between Chili Pepper Consumption and Mortality. Journal of the American College of Cardiology, 2020, 75, 1864.	2.8	5
102	Reconstruction After Salvage Total Laryngectomy: A Costâ€effectiveness Analysis. Otolaryngology - Head and Neck Surgery, 2021, 164, 139-145.	1.9	5
103	Where Do We Go From Here? A Framework for Using Susceptible-Infectious-Recovered Models for Policy Making in Emerging Infectious Diseases. Value in Health, 2021, 24, 917-924.	0.3	5
104	The cost effectiveness of cardiovascular medicines. Current Atherosclerosis Reports, 2005, 7, 79-80.	4.8	4
105	INCREMENTAL EXPENDITURE OF BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC TREATMENT USING INSTRUMENTAL VARIABLES IN PANEL DATA. Health Economics (United Kingdom), 2013, 22, 807-823.	1.7	4
106	Factors Associated with Failure to Achieve SVR in Hepatitis C Genotype 3 Patients Within an Integrated Care Delivery System. Journal of Managed Care & Specialty Pharmacy, 2015, 21, 641-647.	0.9	4
107	Diagnosing newborns with suspected mitochondrial disorders: an economic evaluation comparing early exome sequencing to current typical care. Genetics in Medicine, 2021, 23, 1854-1863.	2.4	4
108	Effects of fluoride and regular dental care on personal dental expenditures of young adults in Finland. Community Dentistry and Oral Epidemiology, 1982, 10, 15-22.	1.9	3

#	Article	IF	CITATIONS
109	Cost of lipid-lowering starin drugs. American Journal of Cardiology, 1996, 77, 225-226.	1.6	3
110	Pharmacoeconomics: Identifying the Issues Overview and Advisory Panel Report Summary. Value in Health, 1999, 2, 67-72.	0.3	3
111	An economic cost analysis of oral ganciclovir prophylaxis for the prevention of CMV disease. , 2000, 17, 911-919.		3
112	Pharmacoeconomic Guidelines: Where Do We Go from Here?. Value in Health, 2001, 4, 211.	0.3	3
113	Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors. Haemophilia, 2013, 19, 711-719.	2.1	3
114	Promise of Precision Medicine. JAMA - Journal of the American Medical Association, 2015, 314, 1752.	7.4	2
115	Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab. Cost Effectiveness and Resource Allocation, 2018, 16, 30.	1.5	2
116	Medicare Pricing Mechanisms for Physician Services: An Overview of Alternative Approaches. Medical Care Review, 1986, 43, 59-100.	0.9	1
117	Comment: Evaluation of Pharmacoeconomic Studies: Utilization of a Checklist. Annals of Pharmacotherapy, 1994, 28, 539-539.	1.9	1
118	Introduction to the ISPOR Lipid Conference. Value in Health, 1998, 1, 95-99.	0.3	1
119	A Direction for Value in Health. Value in Health, 1998, 1, 149-154.	0.3	1
120	Commentary: Pharmacoeconomics and Outcomes Research: Expanding the Healthcare "Outcomes― Market. Value in Health, 2000, 3, 181-185.	0.3	1
121	The Application of Cost-Effectiveness and Cost–Benefit Analysis to Pharmaceuticals. , 2005, , 225-248.		1
122	Medicare Coverage and Reimbursement of Outpatient Prescription Drugs in the US. Applied Health Economics and Health Policy, 2005, 4, 9-14.	2.1	1
123	Comparing Patient Access to Pharmaceuticals in the??UK and US. Applied Health Economics and Health Policy, 2006, 5, 269-270.	2.1	1
124	A six-year study of diagnostic lower extremity imaging practice patterns and outcomes in the Veterans Affairs health care system. International Journal of Angiology, 2008, 17, 78-82.	0.6	1
125	Prices, regulation and innovation in pharmaceuticals and biotechnology. Research in Human Capital and Development, 2007, , 81-99.	0.1	1
126	Marijuana Use in Models for Health Outcomes. American Journal of Medicine, 2015, 128, e23.	1.5	1

#	Article	IF	CITATIONS
127	Hypertension and Unlikely Causality in the Association Between Soft Drink Consumption and Mortality. JAMA Internal Medicine, 2020, 180, 335.	5.1	1
128	Characterizing the Validity and Real-World Utility of Health Technology Assessments in Healthcare: Future Directions Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modelling". International Journal of Health Policy and Management, 2020, 9, 352-355.	0.9	1
129	The ISPOR Lipid Conference: Pharmacoeconomics and Outcomes Modeling Issues. Value in Health, 1998, 1, 155-158.	0.3	0
130	From Research into Practice: How Should Healthcare Organizations/Governments Decide about Lipid Therapy and Who Will Pay? Reactor Panel and Open Forum. Value in Health, 1998, 1, 243-250.	0.3	0
131	Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 545-558.	1.4	0
132	A Special Commemorative Issue Honoring William S. Comanor and 50 Years of Pharmaceutical Economics. International Journal of the Economics of Business, 2015, 22, 165-168.	1.7	0
133	Consistent estimation of polychotomous treatment effects with selection-bias and unobserved heterogeneity using panel data correlated random coefficients model. Health Services and Outcomes Research Methodology, 2018, 18, 75-95.	1.8	0
134	The Assessment of Different Diets and Mortality Fails to Address Unmeasured Confounding. JAMA Internal Medicine, 2021, 181, 137.	5.1	0
135	Current Issues in Pharmacoeconomic Modeling. The Journal of Health Technology Assessment, 2014, 2, 6-9.	0.2	0
136	Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis. BMC Urology, 2022, 22, 76.	1.4	0